tremelimumab,durvalumab,Sorafenib
AstraZeneca,Pfizer
['bcsm', 'hcc']
 not surprising to see that occurrence of immune related adverse events (iraes) has an impact on survival for patients with hepatocellular cancer (hcc) getting the new stride regimen. t3 0 0 d #hpbcsm #asco23 most iraes within 3-months. os: 23m 14.1m 
Oncologist | Researcher | ColorectalCancer #CRCSM👨🏼‍🎓@MayoClinic @PittTweet Alum; 🧬#ctDNA #LiquidBiopsies💡#PrecisionOncology ViewsMy Own. COI @ASCO📍 #GI23